Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Unravelling the behaviour of individual lymphoma cells to find out why the cancer can relapse or resist treatment
Professor Suzanne Turner will investigate the behaviour of individual lymphoma cells in order to find out why treatments fail.
Investigating the role of SET in childhood acute myeloid leukaemia to develop new treatments
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.
Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Exploring how osteosarcoma cells spread and survive elsewhere in the body
Dr Olivier Pardo will investigate how osteosarcoma cells which escape into the bloodstream survive to spread elsewhere in the body.
Stopping the alpha - a potential new treatment approach for osteosarcoma
Professor Plevin and Dr Margaret Cunningham will investigate an enzyme that might play a role in osteosarcoma development, and see whether this could form the basis of a new type of treatment.
Exploring potential indicators of the likely course of disease: analysing blood samples from patients recruited to the rEECur clinical trial
Professor Martin McCabe aims to understand whether blood-based biomarkers could help predict Ewing sarcoma survival.
Harnessing the immune system to treat Ewing sarcoma in the lungs
Dr Jonathan Fisher aims to create an 'off the shelf' version of immunotherapy to for hard-to-treat Ewing sarcoma.